Key result
A zero-fluoroscopy approach to cavotricuspid isthmus catheter ablation using the Carto 3 system achieved similar acute success (95% vs 100%) and complication rates as the Ensite-NavX system.
Why the study?
Does a zero-fluoroscopy approach using the Carto®3 system provide similar feasibility, safety, and efficacy compared to the Ensite-NavX™ system in cavotricuspid isthmus catheter ablation?
Case-Control (n=60)
Does a zero-fluoroscopy approach using the Carto®3 system provide similar feasibility, safety, and efficacy compared to the Ensite-NavX™ system in cavotricuspid isthmus catheter ablation?
Absolute Event Rate: 95% vs 100%
A zero-fluoroscopy approach for cavotricuspid isthmus ablation is highly feasible and safe using the Carto®3 system, with outcomes comparable to the Ensite-NavX™ system.
Zero-fluoroscopy CTI ablation feasible with Carto3; leaves open comparative safety and efficacy versus Ensite-NavX.
BACKGROUND: Electroanatomical mapping systems have reduced the amount of fluoroscopy required to ablate the cavotricuspid isthmus. The aims of this study are to evaluate the feasibility and safety of a zero-fluoroscopy approach to cavotricuspid isthmus catheter ablation using the Carto®3 system (Biosense Webster, Diamond Bar, CA, USA) and to compare the results of this approach with those of the zero-fluoroscopy approach using the Ensite-NavX™ system (St. Jude Medical, St. Paul, MN, USA). METHODS: Twenty consecutive procedures guided by the Carto®3 system (Group A) were compared with two case-control groups matched from 146 procedures guided with the Ensite-NavX™ system. Group B consisted of 20 matched procedures from the first 50 procedures performed in the electrophysiology unit, and Group C consisted of 20 matched procedures from the last 50 procedures. Acute success (bidirectional block), complications, and recurrences were analyzed. The procedure times were also compared. RESULTS: There were no differences in the rates of acute success (95%, 100%, and 100%, respectively), complications (0%, 5%, and 0%), and recurrences (5.2%, 0%, and 5%) in the three groups. A zero-fluoroscopy approach was attempted in all procedures, and electroanatomical mapping made it possible to successfully avoid fluoroscopy in 90% of the procedures in Group A, 85% in B, and 95% in C. The total procedure time was shorter in Group C. The fluoroscopy and radiofrequency times were not different. CONCLUSIONS: A zero-fluoroscopy approach to cavotricuspid isthmus catheter ablation using the Carto®3 system is feasible in most procedures. This approach has similar results to the zero-fluoroscopy approach using the Ensite-NavX™ system.
No takes yet. Share an insight, caveat, or question.
Macías et al. (2014) conducted a case-control in Cavotricuspid isthmus catheter ablation (n=60). Zero-fluoroscopy approach using Carto®3 system vs. Zero-fluoroscopy approach using Ensite-NavX™ system was evaluated on Acute success (bidirectional block). A zero-fluoroscopy approach to cavotricuspid isthmus catheter ablation using the Carto 3 system achieved similar acute success (95% vs 100%) and complication rates as the Ensite-NavX system.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: